Report an error   


Submitted: 04 June 2008 Modified: 28 October 2015
HERDIN Record #: PCHRD060608120633

Olmesartan in Filipino subjects with hypertension: Results from an eight-week, open-label, treat-to-target study.

Annette P. Borromeo,
Isabelo V. Ongtengco Jr,
Edgar Molleno,
Manuel Zacarias,
Eugene B. Reyes,
Ernesto P. Namin,
Donato R. Maranon,
Wing Lowe,
Francisco Tranquillino

See More

OBJECTIVE: To evaluate the efficacy and safety of olmesartan medoxomil (20 mg and 40 mg) in Filipino subjects with mild to moderate essential hypertension. METHODS: Sixty-seven (n = 24 male; n= 43 female) Filipino outpatients (mean age Sl.lill.5 years) with mild to moderate hypertension entered this 8-week, open-label, dose titration, treat-to-target study; n = 62 patients completed. All subjects received olmesartan 20 mg for four weeks, at which time a dose titration assessment occurred. Subjects were either maintained on 20 mg or up-titrated to 40 mg for the final four weeks. Intent-to-treat analysis were performed using last observation carried forward (LOCF) methodology on the percentage of subjects achieving blood pressure (BP) target (responders were pre-specified using the JNC VII guidelines) at Weeks 4 and 8 (primary endpoint). Safety was assessed by incidence of adverse events (AEs) and subject discontinuations. RESULTS: A large proportion of subjects achieved BP target at Week 8/LOCF (59 percent, n = 39); moreover, 48 percent (n-31) responded at Week 4. A further 11, of the 33 subjects not at target at Week 4, went on to achieve BP target by Week 8/LOCF. Overall, mean BP at baseline was 155.4/95.8 mmHg, which was reduced to 127.2/80.3 following eight weeks of treatment. Seven subjects reported 12 treatment-related AEs; the most common was headache (n-3). There were no serious AEs reported during the study and only one subject had severe AEs (headache, insomnia and facial flushing); this subject was the only subject who discontinued due to treatment-related AEs. CONCLUSION: Olmesartan medoxomil was found to be an effective, safe and well-tolerated antihypertensive agent in this Filipino population, with 59% of subjects reaching their BP target by the end of the study. These data are supportive of findings in other populations, and will provide valuable information for Filipino clinicians for management of hypertension.

Publication Type
Journal
Publication Sub Type
Others
Title
Philippine Journal of Internal Medicine
Frequency
Six times a year (6x/year)
Publication Date
March-April 2007
Volume
45
Issue
2
Page(s)
97-102

Objectives

To evaluate the efficacy and safety of olmesartan medoxomil (20 mg and 40 mg) in Filipino subjects with mild to moderate essential hypertension.

LocationLocation CodeAvailable FormatAvailability
Philippine Council for Health Research and Development Library Box No 48 Fulltext pdf (Request Document)
1. Hajjar, I , Kotchen, T A. "Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988 - 2000" JAMA 290, 199, 2003
2. Chobanian, A V, Bakris, G L, Black, H R, et al, . "The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report" JAMA 289, 2560, 2003
3. "Guidelines for the management of hypertension for general practitioners: Japanese Society of Hypertension Guidelines Subcommittee for the management of hypertension " Hypertension Research 24, 613, 2001
4. Gardner, S F, Franks, A M. "Olmesartan medoxomil: The Seventh angiotensin receptor antagonist" Annals Pharmacotherapy 37, 99, 2003
5. "2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension" Journal Hypertension 21, 1011, 2003
6. Warner, G T, Jarvis, B . "Olmesartan medoxomil" Drugs 62, 1345, 2002
7. Whittaker, A . "A Review of olmesartan medoxomil - A New angiotensin II receptor blocker" British Journal of Cardiology 12, 125, 2005
8. Neutel, J M, Elliott, W Z, Izzo, , et al, . "Antihypertensive efficacy of olmesartan medoxomil, A New angiotensin II receptor antagonist. As assessed by ambulatory blood pressure measurements" Journal Clinical Hypertension (Greenwich) 4, 325, 2002
9. Adair, L S. "Dramatic rise in overweight and obesity adult Filipino women and rissk of hypertension" Obesity Research 12, 1335, 2004
10. Mukhopadhyay, B , Sattar, N , Fisher, M . "Diabetes and cardiac disease in South Asians" British Journal Diabetes Vascular Disease 5, 253, 2005
11. Liau, C S, Lee, C M, Sheu, S H, et al, . "Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients" Clinical Drug Investigation 25, 473, 2005
12. CH Yiannakopoulou, E , Papadopulos, J S, Cokkinos, D V, et al, . "Adherence to antihypertensive treatment: A Critical factor for blood pressure control" European Journal of Cardiovascular Prev Rehabilitation 12, 243, 2005
13. Domino, F J. "Improving adherence to treatment for hypertension" American Family Physician 71, 2089, 2005
14. Lowry , K P, Dudley, T K, Oddone, E Z, et al, . "Intentional and unintentional nonadherence to antihypertensive medication" Annals Pharmacotherapy 39, 1198, 2005
15. Brunner, H R. "The New oral angiotensin II antagonist olmesartan medoxomil: A Concise overview" Journal Human Hypertension 16(Suppl 2): S13, 2002
16. Brunner, H R, Laelis, P . "Clinical efficacy of olmesartan medoxomil" Journal Hypertension 21(Suppl 2): S43, 2003
17. Chrysant, S G, Chrysant , G S. "Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide" Expert Opinion Pharmacother 5, 657, 2004
18. Neutel, J M. "Clinical studies of CS-866. The Newest angiotensin II receptor antagonist" American Journal Cardiology 87, 37C, 2001
19. Yoshida, K , Kohzuki, M . "Clinical and experimental aspects of olmesartan medoxomil. A new angiotensin II receptor antagonist" Cardiovascular Drug Reviews 22, 285, 2004
20. Stumpe, K O, Ludwig, M . "Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs" Journal Human Hypertens 16, S24, 2002
21. Volpe, M . "Treatment of systolic hypertension: Spotlight on recent studies with angiotensin II antagonists" Journal Human Hypertens 19, 93, 2005
22. Ohta, Y , Tsuchihashi, T , Fujji, K , et al, . "Improvement of blood pressure control in hypertension clinic: A 10-year follow-up study" Journal Human Hypertens 18, 273, 2004
23. Smith, D . "Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade" American Journal Hypertens 15, S108, 2002
24. Turnbull, F . "Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Blood pressure lowering treatment trialists" Lancet 362, 1527, 2003
25. Reyes-Gibby, C C, Aday, L A. "Prevalence of and risk factors for hypertension in a rural area of the Philippines" Journal Community Health 25, 389, 2000